[C:1]([O:5][C:6]([NH:8][C:9]1([C:13]([OH:15])=O)[CH2:12][O:11][CH2:10]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[N:16]1[CH:21]=[CH:20][CH:19]=[CH:18][C:17]=1[C:22]1([NH2:25])[CH2:24][CH2:23]1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.C(N(CC)CC)C>CN(C=O)C.CO.O>[C:1]([O:5][C:6](=[O:7])[NH:8][C:9]1([C:13](=[O:15])[NH:25][C:22]2([C:17]3[CH:18]=[CH:19][CH:20]=[CH:21][N:16]=3)[CH2:24][CH2:23]2)[CH2:10][O:11][CH2:12]1)([CH3:2])([CH3:3])[CH3:4]A solution of 3-tert-butoxycarbonylamino-oxetane-3-carboxylic acid (82 mg, 0.38 mmol), 1-pyridin-2-yl-cyclopropylamine (56 mg, 0.42 mmol), HATU (215 mg, 0.57 mmol), and triethylamine (77 μL, 0.57 mmol) in DMF (0.5 mL) was stirred at room temperature for 29 h. Water (0.2 mL) and MeOH (1 mL) were added, and the resulting clear solution was purified directly by reverse phase HPLC to give [3-(1-pyridin-2-yl-cyclopropylcarbamoyl)-oxetan-3-yl]-carbamic acid tert-butyl ester as a tan solid (132 mg, >100%) after lyophilization, m/z 334.8 [M+1]+, that was carried on without further purification.